Table 4. Sensitivity, specificity and accuracy of each modality when the least experienced reviewer was excluded.

Diagnostic category	Diagnostic modality	Sensitivity (95 % CI)	Specificity (95 % CI)	Accuracy (95 % CI)
Group 1 Adenocarcinoma	EUS-E	95.7 % (89.5 – 98.8)	53.5 % (43.2 – 63.5)	74.7 % (65.0 – 82.9)
	CH-EUS	66.2 % (56 – 75.4)	42.9 % (33.0 – 53.2)	64.4 % (54.2 – 73.7)
	Combination	92 % (84.8 – 96.5)	61 % (50.7 – 70.6)	78 % (68.6 – 85.7)
Group 2 PNET	EUS-E	57.9 % (47.6 – 67.7)	93.1 % (86.1 – 97.3)	85.7 % (77.2 – 92.0)
	CH-EUS	46.7 % (36.6 – 57.0)	93.3 % (86.4 – 97.4)	85.6 % (77.1 – 91.9)
	Combination	66.7 % (56.5 – 75.8)	94.5 % (88.1 – 98.1)	89 % (81.2 – 94.4)
Group 3 Inflammatory	EUS-E	41.7 % (31.9 – 52.0)	100 %	84.6 % (75.9 – 91.1)
	CH-EUS	35 % (25.7 – 45.2)	88.6 % (80.6 – 94.2)	76.7 % (67.1 – 84.6)
	Combination	43.5 % (33.6 – 53.8)	95.5 % (89.4 – 98.6)	82.4 % (73.5 – 89.3)